Chromogranin A as a determinant of midgut carcinoid tumour volume

被引:42
作者
Kölby, L [1 ]
Bernhardt, P
Swärd, C
Johanson, V
Ahlman, H
Forssell-Aronsson, E
Stridsberg, M
Wängberg, B
Nilsson, O
机构
[1] Univ Gothenburg, Dept Surg, Inst Surg Sci, Sahlgrenska Hosp, SE-41345 Gothenburg, Sweden
[2] Univ Gothenburg, Lundberg Lab Canc Res, Sahlgrenska Hosp, SE-41345 Gothenburg, Sweden
[3] Univ Gothenburg, Dept Radiat Phys, Sahlgrenska Hosp, SE-41345 Gothenburg, Sweden
[4] Univ Uppsala Hosp, Dept Med Sci Clin Chem, S-75185 Uppsala, Sweden
[5] Univ Gothenburg, Sahlgrenska Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden
关键词
chromogranin A; neuroendocrine; carcinoid tumours; octreotide;
D O I
10.1016/j.regpep.2004.03.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neuroendocrine (NE) tumours are characterized by their capacity to synthesize, store and release hormonal products. These substances are stored in neurosecretory vesicles together with chromogranin A (CgA). The concentration of plasma CgA in patients with NE tumours is thought to reflect the degree of NE differentiation, total tumour burden and effect of medical treatment. The aim of this study was to analyse the correlation between tumour weight and plasma CgA levels as well as the influence of treatment with a long-acting somatostatin analogue (octreotide) using nude mice with xenografted human ileal carcinoid tumours. There was a correlation between tumour weight and plasma CgA levels in all animals (p < 0.00001). In octreotide-treated mice, plasma CgA levels were significantly reduced versus untreated animals (p = 0.037). In conclusion, this study demonstrates that plasma CgA levels are closely correlated to tumour burden, and that plasma CgA is well suited for monitoring the clinical course and outcome of treatment in patients with NE tumours. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:269 / 273
页数:5
相关论文
共 36 条
[1]   Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [J].
Arnold, R ;
Trautmann, ME ;
Creutzfeldt, W ;
Benning, R ;
Benning, M ;
Neuhaus, C ;
Jurgensen, R ;
Stein, K ;
Schafer, H ;
Bruns, C ;
Dennler, HJ .
GUT, 1996, 38 (03) :430-438
[2]  
Bajetta E, 1999, CANCER, V86, P858, DOI 10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO
[3]  
2-8
[4]  
BANKS P, 1965, BIOCHEM J, V97, P40
[5]   Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours [J].
Baudin, E ;
Gigliotti, A ;
Ducreux, R ;
Ropers, J ;
Comoy, E ;
Sabourin, JC ;
Bidart, JM ;
Cailleux, AF ;
Bonacci, R ;
Ruffié, P ;
Schlumberger, M .
BRITISH JOURNAL OF CANCER, 1998, 78 (08) :1102-1107
[6]   SECRETION OF A CHROMAFFIN GRANULE PROTEIN CHROMOGRANIN FROM ADRENAL GLAND AFTER SPLANCHNIC STIMULATION [J].
BLASCHKO, H ;
COMLINE, RS ;
SCHNEIDER, FH ;
SILVER, M ;
SMITH, AD .
NATURE, 1967, 215 (5096) :58-+
[7]   Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis [J].
Borch, K ;
Stridsberg, M ;
Burman, P ;
Rehfeld, JF .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (03) :198-202
[8]   Antiproliferative effect of somatostatin and analogs [J].
Bousquet, C ;
Puente, E ;
Buscail, L ;
Vaysse, N ;
Susini, C .
CHEMOTHERAPY, 2001, 47 :30-39
[9]   PLASMA CHROMOGRANIN-A MARKS EMESIS AND SEROTONIN RELEASE ASSOCIATED WITH DACARBAZINE AND NITROGEN-MUSTARD BUT NOT WITH CYCLOPHOSPHAMIDE BASED CHEMOTHERAPIES [J].
CUBEDDU, LX ;
OCONNOR, DT ;
HOFFMANN, I ;
PARMER, RJ .
BRITISH JOURNAL OF CANCER, 1995, 72 (04) :1033-1038
[10]   CHROMOGRANIN-A - ITS ROLE IN ENDOCRINE FUNCTION AND AS AN ENDOCRINE AND NEUROENDOCRINE TUMOR-MARKER [J].
DEFTOS, LJ .
ENDOCRINE REVIEWS, 1991, 12 (02) :181-187